Assessing an ICD-10 code approach for estimating xylazine-involved overdose deaths in the United States

Abstract

Introduction

The prevalence of the veterinary sedative xylazine in US overdose deaths rose between 2018 and 2021. More updated estimates are limited, partially due to the lack of a dedicated ICD-10 code—a primary mechanism used to specify drugs implicated in overdose deaths in the US, including in the CDC WONDER system, which provides public data for download with a 6-month lag. For other emerging substances lacking dedicated codes, over time umbrella codes have come to de facto represent them, yet it has not been demonstrated if this has occurred for xylazine.

Methods

Overdose deaths in CDC WONDER involving T42.7 (“Antiepileptic and sedative-hypnotic drugs, unspecified”) or T46.5 (“Other antihypertensive drugs, not elsewhere classified”) were compared to two more specific, albeit delayed, sources: NVSS describing national trends in 2018–2021 and SUDORS describing state-level trends in 2020–2022. This CDC WONDER approach was also used to estimate trends in xylazine-involved deaths through 2024 Q1 by geography, race/ethnicity, substance co-involvement, and demographic categories.

Results

At the national level, concordance between CDC WONDER records and previous NVSS estimates improved after 2019 and became highly similar in 2021 (3480 vs 3468 deaths). Concordance was also high for estimates stratified by race, age, and region. At the state-level, across 49 state-year pairs, correlation between CDC WONDER and SUDORS was 0.97. Estimated xylazine-involved deaths doubled between 2021 and 2024 Q1, and estimated racial inequalities widened.

Discussion

T42.7 or T46.5, together, may have become the de facto coding scheme representing xylazine-involved deaths. This approach provides more up-to-date estimates, showing increasing prevalence and worsening racial inequalities in xylazine-involved deaths into 2024.